DOÇ.DR. TUĞBA AKIN TELLİ

1.    Kılıçtaş B, Araz M, Oruç A, Çağlayan D, Emin G, Yıldırım A, Aydın Tİ, Hacıoğlu MB, Dişli AK, İnanç M, Uyar GC, Çakmak Öksüzoğlu ÖB, Uysal M, Koçanoğlu A, Akın Telli T, Akdağ G, Kınıkoğlu O, Işık D, Arcagök M, Urakçı Z, Şahin E, Akdoğan O, Danacı Y, Şakalar T, Avcı N, Serin Özel G, Doğu GG, Şahin Hafızoğlu E, Erdoğan AP, Alkan A, Erkan Özmarasalı B, Deligönül A, Büyükşimşek M, Karakurt Eryılmaz M, Artaç M. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study. J Chemother. 2025 Dec 19:1-13. doi: 10.1080/1120009X.2025.2601938. 

2.    Tunbekici S, Sahin G, Ön S, Oruc A, Eryılmaz MK, Sakin A, Coskun A, Seyyar M, Uzundere FK, Kolemen E, Cabuk D, Efil SC, Demir T, Turkmen E, Ekinci F, Terzi A, Sahin TK, Guven DC, Aksoy S, Aytac A, Demirkıran Ö, Demir B, Culcuoglu I, Ersoy M, Asarkaya E, Camanlı U, Gezici B, Ozveren A, Sevınc A, Kitaplı S, Unlu A, Ozturk B, Turkel A, Dogan M, Aslan F, Yesilbas E, Kaplan E, Sakalar T, Sahin E, Emin G, Asık E, Yıldırım A, Guclu T, Ugurlu I, Kahvecioglu F, Hacıbekiroglu I, Tunbekici I, Bayram S, Kaya AO, Majidova N, Yalıcı O, Karateke M, Avcı N, Belen B, Bal H, Kınıkoglu O, Turkoz FP, Sımsek ET, Altınok O, Gunes TK, Altıntas YE, Guliyev M, Ozturk G, Erdem D, Duzkopru Y, Inal A, Guren AK, Yıldırım N, Telli TA, Danacı Y, Aydın U, Almuradova E, Yıldırım HC, Gursoy P, Sendur MAN, Goker E. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group. Int J Cancer. 2025 Oct 28.

3.    Demircan NC, Tekin MF, Akın Telli T, Arıkan R, Başoğlu T, Çelebi A, Yaşar A, Işık S, Ercelep Ö, Dane F, Ataizi Çelikel Ç, Yumuk PF. Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups. Future Oncol. 2025 Oct 5:1-10. 

4.    Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Mocan EE, Demirkazık A, Kahraman S, Şendur MA, Doğan M, Selam MT, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren OÖ, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group. Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00159-7. doi:

5.    Alan O, Telli TA, Akbas S, Isik S, Çavdar E, Karaboyun K, Merc Cetinkaya A, Ekinci F, Erdoğan AP, Büyükşimsek M, Er MM, Karakurt Eryilmaz M, Güçlü Kantar T, Gököz Doğu G, Sakalar T, Bayram E, Inal A, Akdağ Kahvecioğlu F, Hacibekiroğlu İ, Selçukbiricik F, Tatli AM, Yumuk PF. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations. Medicina (Kaunas). 2025 Jun 26;61(7):1160. 

6.    Arıkan R, Demircioğlu Ö, Özgüven S, Demircan NC, Alan Ö, Telli TA, Işık S, Başoğlu T, Çelebi A, Yaşar A, Şahin CÖ, Ercelep Ö, Dane F, Cimşit C, Yumuk PF. Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy. Indian J Cancer. 2024 Oct 1;61(4):789-796. 

7.    Deliktaş Onur İ, Başoğlu T, Demircan NC, Akin Telli T, Arikan R, Ercelep Ö, Turhal NS, Öztürk MA, Yumuk PF, Dane F. Evaluating the performance of the MSKCC gastric cancer survival calculator in the Turkish population. Turk J Med Sci. 2024 Jul 4;54(6):1205-1214. 

8.    Peker Eyüboğlu İ, Koca S, Çelik B, Güllü Amuran G, Uğurlu MÜ, Alan Ö, Akın Telli T, Yumuk PF, Akkiprik M. Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients. Int J Breast Cancer. 2024 Nov 14;2024:6117394.

9.    Çelik B, Peker Eyüboğlu İ, Koca S, Uğurlu MÜ, Alan Ö, Güllü Amuran G, Akin Telli T, Yumuk F, Akkiprik M. Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT. Turk J Med Sci. 2024 Mar 11;54(4):652-665. 

10.    Filizoglu N, Ozguven S, Akin Telli T, Ones T, Dede F, Turoglu HT, Erdil TY. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/ computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors. Nucl Med Commun. 2024 Aug 1;45(8):736-744.

11.    Assaf I, Fimereli D, Anthoine G, Fazio R, Daprà V, Audisio A, Bardiaux A, Telli TA, Vanhooren M, Saude-Conde R, Bregni G, Hendlisz A, Sclafani F. Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer. Cancers (Basel). 2023 Dec 13;15(24):5823. 

12.    Arikan R, Akin Telli T, Isik S, Sari M, Kostek O, Ercelep O, et al. Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience. EJMI 2023;7(3):296–302.

13.    Akyildiz A, Guven DC, Ozluk AA, Ismayilov R, Mutlu E, Unal OU, Yildiz I, Iriagac Y, Turhal S, Akbas S, Bayram E, Telli TA, Turkoz FP, Ozcelik M, Erciyestepe M, Selvi O, Gulbagci B, Erturk I, Isleyen ZS, Kahraman S, Akdag MO, Hamitoglu B, Unek IT, Unal C, Hacibekiroglu İ, Arslan C, Azizy A, Helvaci K, Demirci U, Dizdar O, Basaran M, Goker E, Sendur MA, Yalcin S. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. Medicine (Baltimore). 2023 Nov 10;102(45):e35950. 

14.    Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, Sen E, Telli TA, Karatas F, Gokmen I, Turhal NS, Sakalar T, Ayhan M, Ekinci F, Hafizoglu E, Kahraman S, Kesen O, Unal C, Alan O, Celik S, Yekeduz E, Omur O, Gokmen E. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749. 

15.    Rukiye Arıkan, Hilal Sağıroğlu Üstün, Nazım Can Demircan, Selver Işık, Tuğba Akın Telli, Alper Yaşar, Abdussamet Çelebi, Nargiz Majidova, Nadiye Sever, Çiğdem Çelikel, Murat Sarı, Özlem Ercelep, Osman Köstek, İbrahim Vedat Bayoğlu. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib. J Oncol Sci. 2023;9(2):53-61.


16.    Ugurlu MU, Bugdayci O, Akmercan A, Kaya H, Akin Telli T, Akoglu H, Gulluoglu BM. Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple? Breast Cancer Res Treat. 2023 Oct;201(3):417-424.

17.    Arikan, R., Atci, M. M., Ay, S., Ayhan, M., Demircan, N. C., Telli, T. A., Çelebi, A., Yaşar, A., Işik, S., Celikel, C., Balvan, O., Bayoglu, I. V., Kostek, O., Dane, F., Yumuk, P. F. Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. 

18.    Sinan Koca,  Nalan Akgul Babacan,  Ilker Nihat Okten, Tugba Akin Telli,  Ozkan Ala,  Bilge Aktas Sezen,  Faysal Dane, Perran Fulden Yumuk. The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer. EJMI 2023;7(2):170–174. 

19.    Sinan Koca, Ilker Nihat Okten, Mehmet Besiroglu, Tugba Akin Telli, Ayse Demirci, Mustafa Karaagac, Ahmet Kucukarda, Semiha Urvay, Sedat Tarik Firat, Zeynep Oruc, Mehmet Murat Zerey, Ezgi Coban, Ibrahim Cil, Mahmut Gumus. Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study. EJMO 2023;7(1):34–41.

20.    Bregni G, Trevisi E, Saúde Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F. Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review. J Natl Cancer Inst. 2023 May 8; 115(5):505-513. 

21.    Tuğba Başoğlu, Nazım Can Demircan, Rukiye Arıkan, Tugba Akın Telli, Selver Işık, Alper Yasar, Abdussamet Çelebi, Özlem Ercelep, Faysal Dane, Perran Fulden Yumuk.  Comparison of Resected Ampullary and Pancreatic Head Carcinomas: A Single-Center Experience. South. Clin. Ist. Euras. 2022;33(3):326-330. 

22.    Basoglu T, Babacan NA, Ozturk FE, Arikan R, Demircan NC, Telli TA, Ercelep O, Dane F, Yumuk PF. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma. Indian J Cancer 2023 Apr-Jun;60(2):179-184.

23.    Özgür G, Çetin M, Telli T, Filinte D, Tinay İ. Testicular Metastasis in Renal Cell Carcinoma. J Urol Surg, 2022;9(4):306-308. 

24.    Telli TA, Alan O, Demircan NC, Sariyar N, Arikan R, Basoglu T, Yasar A, Celebi A, Isik S, Sofulu O, Erol B, Turkoz HK, Ozgen Z, Ercelep O, Dane F, Yumuk PF. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities. Orthop Traumatol Surg Res. 2023 May;109(3):103491.

25.    Arikan R, Ozguven S, Telli TA, Isik S, Demircan NC, Basoglu T, Yasar A, Celebi A, Filizoglu N, Ustun HS, Tinay I, Ones T, Turoglu HT, Erdil TY, Ozturk MA, Ercelep O, Bayoglu V, Kostek O, Dane F, Yumuk PF. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. Acta Radiol. 2023 May;64(5):2040-2049.

26.    Tugba Basoglu, Salih Ozguven, Ceren Ozge Engur, Firat Akagunduz, Nazim Can Demircan, Rukiye Arikan, Fatma Temiz,  Selma Sengun,  Selver Isik,  Tugba Akin Telli,  Abdussamed Celebi, Alper Yasar, Ozlem Ercelep, Faysal Dane, Yumuk, P. F.. Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. EJMI 2023;7(1):32–41.

27.    Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/ microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev. 2022 Nov;110:102460. 

28.    Nazım Can Demı̇rcan, Ceren Özge Engür, Tuğba Akın Tellı̇, Tuğba Başoğlu, Rukiye Arıkan,  Alper Yaşar,  Abdussamet Çelebı̇,  Özkan Alan,  Selver Işık, Salih Özgüven,  Özlem Ercelep, Faysal Dane, Handan Kaya,  Tunç Öneş, Perran Fulden Yumuk. Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib. Turk J Oncol 2022;37(4):379–87.

29.    Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148.

30.    Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, Isik S, Arikan R, Demircan NC, Basoglu T, Cetin IA, Ones T, Ercelep O, Dane F, Yumuk PF. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022 Nov;36(11):964-975.


31.    Tugba Basoglu, Nazim Can Demircan, Tugce Kubra Gunes, Mehmet Umut Capar, Merve Cinar, Rukiye Arikan, Tugba Akin Telli, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk. A Laboratory Prognostic Index Model for Predicting Survival in Patients with Malignant Pleural Mesothelioma. EJMI 2022;6(3):352–358.

32.    Telli TA, Ozturk MA, Alan O, Hasanov R, Kostek O, Arikan R, Basoglu T, Kaya S, Ercelep O, Babacan NA, Dane F, Yumuk PF. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncol. 2022 Jul;18(22):2425-2439.

33.    Özdemir Ö, Zengel B, Yildiz Y, Oyan Uluç B, Çabuk D, Özden E, Kivrak Salim D, Paydas S, Demir A, Diker Ö, Nur Pilanci K, Uysal Sönmez Ö, Vatansever S, Doğan İ, Gülmez A, Çakar B, Gürsoy P, Emre Yildirim M, Ayhan M, Karadurmuş N, Bariş Aykan M, Tuğba Çevik G, Şakalar T, Hacibekiroğlu İ, Belen Gülbağci B, Dinçer M, Bayir Garbioğlu D, Kemal Y, Nayir E, Taşkaynatan H, Yilmaz M, Avci O, Sari M, Çoban E, Mustafa Atci M, Aktürk Esen S, Akin Telli T, Karataş F, İnal A, Demir H, Önal Kalkan N, Yilmaz C, Taşli F, Alacacioğlu A. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670.

34.    Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Nahit Şendur MA. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582.

35.    Telli TA, Bugdayci O, Alan O, Sariyar N, Isik S, Arikan R, Yasar A, Majidova N, Celebi A, Erol B, Ozgen Z, Kostek O, Bayoglu IV, Ercelep O, Dane F, Yumuk PF. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma. Nutr Cancer. 2022;74(7):2499-2507.

36.    Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875.

37.    Akın Telli T, Akgül Babacan N, Alan Ö, Öztürk MA, Hasanov R, Koca S, Halil S, Tanrıkulu Şimşek E, Başoğlu T, Ercelep Ö, Dane F, Yumuk PF. The Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers. Nam Kem Med J 2022;10:74-79.

38.    Atci MM, Akagunduz B, Demir M, Dönmez Yılmaz B, Akin Telli T, Can O, Cil İ, Göktaş Aydın S, Ozyurt N, Önder AH, Selvi O, Sakin A. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated With Concurrent Chemoradiation: A Multicenter Study. Oncol Res Treat. 2022;45(5):254-261. 

39.    Başoğlu T, Akar KE, Bağcı P, Akgül Babacan N, Öztürk MA, Öztürk FE, Demircan NC, Arikan R, Akın Telli T, Ercelep Ö, Dane F, Yumuk PF. Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma. Balkan Med J. 2022 Jan 25;39(1):12-20. 

40.    Nazım Can DEMİRCAN, Tuğba AKIN TELLİ, Tuğba BAŞOĞLU, Alper YAŞAR, Abdussamet ÇELEBİ, Özkan ALAN, Selver IŞIK, Faysal DANE, Perran Fulden YUMUK. Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience. J Oncol Sci. 2021;7(3):133-8.

41.    Baran Akagunduz, Tugba Akin Telli, Hasan Cagri Yıldırım, Sema Sezgin Goksu, Nazan Demır, Emre Hafızoglu, Muhammet Ozer, Gokcen Tugba Cevık, Abdullah Sakın, Sabin Goktas Aydın, Nilay Sengul Samancı, Neslihan Ozyurt, Muhammed Mustafa Atcı, Murat Ayhan, Merve Turan, Nisanur Sarıyar, Cengiz Karacın, Saadettin Kılıckap, Semra Paydas, Mutlu Dogan.  Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group. International Journal of Hematology and Oncology, 2021, 31.2: 092-098.

42.    Başoğlu, T., Özgüven, S., Özkan, H. Ş., Çınar, M., Köstek, O., Demircan, N. C., Arikan, R., Telli, T.A., Ercelep, Ö., Kaya, H., Öneş, T., Erdil, T.Y., Uğurlu, M.Ü., Dane F, Yumuk, P. F. (2021). Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 May-Jun; 41(3):171-178. 

43.    Ali Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, Serkan Değirmencioğlu, Mutlu Doğan, Tuğba Akın Telli, Özge Keskin, Çağatay Arslan, Burak Bilgin, Sema Sezgin Göksu, Hacer Demir, Elif Berna Köksoy, Osman Köstek, İsmail Ertürk, Teoman Şakalar, Arzu Yaşar, Görkem Türkkan, Büşra Kasım, Aziz Karaoğlu, Berna Çakmak Öksüzoğlu, Fulden Yumuk, Mehmet Ali Şendur, Hasan Şenol Coşkun, İrfan Çiçin, Nuri Karadurmuş, Özgür Tanrıverdi, Hakan Akbulut, Yüksel Ürün. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients. J. Mens. Health 2021, 17(4), 128-134. 

44.    Tugba Akin Telli, Nisanur Sariyar, Ozkan Alan, Nazim Can Demircan, Selver Isik, Rukiye Arikan, Tugba Basoglu, Alper Yasar, Abdussamet Celebi, Omer Sofulu, Bulent Erol, Huseyin Kemal Turkoz, Zerrin Ozgen, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk. Preoperative Prognostic Nutritional Index is a Strong Predictor of Survival in Patients with Localized Soft Tissue Sarcoma. EJMI 2021;5(2):256–262.  

45.    Arta Fejzullahu, Tugba Akin Telli, Irem Peker Eyuboglu, Perran Fulden Yumuk and Ahmet Ilter Guney. Expression of NF-κB Regulators (BCL-3, NFKB1, NFKB2) in Metastatic Breast Cancer Patients. Cancer Sci Res 4.3 (2021): 1-9.

46.    Rukiye Arikan, Tugba Akin Telli, Ozkan Alan, Nazim Can Demircan, Tugba Basoglu, Ozlem Ercelep, Handan Kaya, Onur Bugdayci, Umit Ugurlu, Zerrin Ozgen, Faysal Dane, Perran Fulden Yumuk. Clinicopathologic and Radiologic Characteristics of Pleomorphic Lobular Breast Cancer. EJMI 2021;5(1):148–152. 

47.    Akagündüz B, Akin Telli T, Sezgin Goksu S, et al. (February 13, 2021) Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery. Cureus. 2021 Feb 13;13(2):e13324. 

48.    Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Sakar M, Bozkurt S, Atasoy BM, Dane F, Ziyal Mİ, Yumuk PF. Impact of prognostic nutritional index on survival in recurrent glioblastoma. Neurocirugia (Astur). 2021 Jan 13:S1130-1473(20)30136-6. English, Spanish. 

49.    Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. J BUON. 2020 Jul-Aug;25(4):1897-1903. 

50.    Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Curr Probl Cancer. 2021 Apr;45(2):100668. 

51.    Camera S*, Akin Telli T*, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, Hendlisz A. Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. Cancers (Basel). 2020 Sep 24;12(10):E2752. (*equal contributor)

52.    Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, Kaya S, Ugurlu MU, Kaya H, Akgul Babacan N, Dane F, Yumuk PF. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? World J Surg Oncol. 2020 Sep 9;18(1):242. 

53.    Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori. 2021 Jun; 107(3):231-237. 

54.    Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. Acta Oncol. 2020 Dec;59(12):1438-1446. 

55.    Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. Clin Colorectal Cancer. 2020 Dec;19(4):311-318.e1. 

56.    Ercelep, Ö., Telli, T. A., Alan Ö,, Hasanov, R., Şimşek, E. T., Babacan, N. A., Kaya, S., Kaya, H., Dane, F., Yumuk, P. F. (2020). Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment? Single-Center Experience. Turk J Oncol 2020;35(3):334–9. 

57.    Akın Telli T,Esin E,Yalçın Ş. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan Med J. 2020 Aug 11;37(5):281-286.

58.    Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Bozkurt S, Atasoy BM, Dane F, Yumuk PF. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment. Clin Neurol Neurosurg. 2020 Sep;196:105976. 

59.    Demircan NC, Akın Telli T, Başoğlu Tüylü T, Arıkan R, Kocakaya D, Şahin AA, Ercelep Ö, Dane F, Yumuk PF. QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer. Curr Probl Cancer. 2020 Dec;44(6):100594.

60.    Basoglu T, Telli TA, Demircan NC, Arikan R, Ercelep O, Ozguven S, Soysal S, Memisoglu A, Dane F, Yumuk PF. A rare case of gastric cancer with bilateral breast metastasis during pregnancy. J Oncol Pharm Pract. 2021 Jan;27(1):220-226.

61.    Alan O, Telli TA, Tuylu TB, Arikan R, Demircan NC, Ercelep O, Kaya S, Babacan NA, Atasoy BM, Bozkurt S, Bayri Y, Gul D, Ekinci G, Ziyal I, Dane F, Yumuk PF. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. J Oncol Pharm Pract. 2021 Mar;27(2):329-339.